post image

Global Preventive Vaccines Market 2024-2033 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity

  • Report ID: 3399
  • Date: Sep, 2021
  • Pages: 211
  • Category: Healthcare & Pharmaceuticals


Global preventive vaccines market will reach $120.07 billion by 2033, growing by 6.4% annually over 2024-2033, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.

Highlighted with 111 tables and 87 figures, this 211-page report “Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. 

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides forecast from 2024 till 2033 with 2023 as the base year. 

(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

•    Market Structure 
•    Growth Drivers 
•    Restraints and Challenges
•    Emerging Product Trends & Market Opportunities
•    Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region. 

Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2024-2033 included in each section. 

•    Live/Attenuated Vaccines
•    Inactivated Vaccines
•    Subunit Vaccines
•    Toxoid Vaccines
•    Conjugate Vaccines
•    mRNA Vaccines
•    Recombinant Vector Vaccines
•    Other Vaccines

Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2024-2033 included in each section. 

•    Pneumococcal Disease
•    Poliovirus
•    Hepatitis
•    Influenza
•    Measles, Mumps, and Rubella (MMR)
•    Varicella
•    Human Papilloma Virus
•    COVID-19
•    Other Diseases

By Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2024-2033 included in each section. 

•    Intramuscular Route
•    Subcutaneous Route
•    Oral Route
•    Intravenous Injection
•    Other Administration Routes

By Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2024-2033 included in each section. 

•    Pediatric Vaccines
o    Pneumococcal
o    Measles, Mumps, and Rubella (MMR)
o    Varicella
o    Hepatitis
o    Poliovirus
o    Haemophilus Influenzae B (HIB) 
o    Other Diseases
•    Adult Vaccines
o    Influenza
o    Cervical Cancer
o    Hepatitis
o    Zoster
o    Other Diseases

Geographically, the following regions together with the listed national/local markets are fully investigated:

•    North America (U.S., Canada, and Mexico)
•    Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
•    APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
•    South America (Brazil, Chile, Argentina, Rest of South America)
•    MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)

For each region and country, detailed analysis and annual revenue ($ mn) are available for 2024-2033. The breakdown of all regional markets by country and the breakdown of each national market by Vaccine Type, Disease, and Administration over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players: 

AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd. 

(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)


1 Introduction    10
1.1 Industry Definition and Research Scope    10
1.1.1 Industry Definition    10
1.1.2 Research Scope    11
1.2 Research Methodology    14
1.2.1 Overview of Market Research Methodology    14
1.2.2 Market Assumption    15
1.2.3 Secondary Data    15
1.2.4 Primary Data    15
1.2.5 Data Filtration and Model Design    16
1.2.6 Market Size/Share Estimation    17
1.2.7 Research Limitations    18
1.3 Executive Summary    19
2 Market Overview and Dynamics    22
2.1 Market Size and Forecast    22
2.1.1 Impact of COVID-19 on World Economy    24
2.1.2 Impact of COVID-19 on the Market    27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery    29
2.2 Major Growth Drivers    33
2.3 Market Restraints and Challenges    39
2.4 Emerging Opportunities and Market Trends    42
2.5 Porter’s Fiver Forces Analysis    46
3 Segmentation of Global Market by Vaccine Type    50
3.1 Market Overview by Vaccine Type    50
3.2 Live/Attenuated Vaccines    52
3.3 Inactivated Vaccines    53
3.4 Subunit Vaccines    54
3.5 Toxoid Vaccines    55
3.6 Conjugate Vaccines    56
3.7 mRNA Vaccines    57
3.8 Recombinant Vector Vaccines    58
3.9 Other Vaccines    59
4 Segmentation of Global Market by Disease    60
4.1 Market Overview by Disease    60
4.2 Pneumococcal Disease    62
4.3 Poliovirus    63
4.4 Hepatitis    64
4.5 Influenza    65
4.6 Measles, Mumps, and Rubella (MMR)    66
4.7 Varicella    67
4.8 Human Papilloma Virus    68
4.9 COVID-19    69
4.10 Other Diseases    70
5 Segmentation of Global Market by Administration    71
5.1 Market Overview by Administration    71
5.2 Intramuscular Route    73
5.3 Subcutaneous Route    74
5.4 Oral Route    75
5.5 Intravenous Injection    76
5.6 Other Administration Routes    77
6 Segmentation of Global Market by Patient    78
6.1 Market Overview by Patient    78
6.2 Pediatric Vaccines    80
6.3 Adult Vaccines    82
7 Segmentation of Global Market by Region    84
7.1 Geographic Market Overview 2022-2032    84
7.2 North America Market 2022-2032 by Country    88
7.2.1 Overview of North America Market    88
7.2.2 U.S.    92
7.2.3 Canada    96
7.2.4 Mexico    99
7.3 European Market 2022-2032 by Country    102
7.3.1 Overview of European Market    102
7.3.2 Germany    106
7.3.3 U.K.    109
7.3.4 France    112
7.3.5 Spain    115
7.3.6 Italy    118
7.3.7 Russia    121
7.3.8 Rest of European Market    124
7.4 Asia-Pacific Market 2022-2032 by Country    126
7.4.1 Overview of Asia-Pacific Market    126
7.4.2 Japan    130
7.4.3 China    134
7.4.4 Australia    137
7.4.5 India    140
7.4.6 South Korea    143
7.4.7 Rest of APAC Region    146
7.5 South America Market 2022-2032 by Country    148
7.5.1 Argentina    151
7.5.2 Brazil    154
7.5.3 Chile    157
7.5.4 Rest of South America Market    160
7.6 MEA Market 2022-2032 by Country    161
7.6.1 UAE    164
7.6.2 Saudi Arabia    167
7.6.3 South Africa    170
7.6.4 Other National Markets    173
8 Competitive Landscape    174
8.1 Overview of Key Vendors    174
8.2 New Product Launch, Partnership, Investment, and M&A    177
8.3 Company Profiles    178
AstraZeneca plc    178
Bavarian Nordic A/S    180
China National Biotec Group Company Ltd.    183
CSL Ltd.    185
Daiichi Sankyo Co. Ltd    187
Emergent BioSolutions Inc.    189
GlaxoSmithKline plc    191
Johnson & Johnson    195
Merck & Co.    197
Moderna Inc.    199
Novavax, Inc.    200
Pfizer Inc.    202
Sanofi SA    206
Takeda Pharmaceutical Co. Ltd.    209
RELATED REPORTS    211


List of Tables

Table 1.  Snapshot of Global Preventive Vaccines Market in Balanced Perspective, 2022-2032    20
Table 2. World Economic Outlook, 2021-2031    25
Table 3. World Economic Outlook, 2021-2023    26
Table 4. Scenarios for Economic Impact of Ukraine Crisis    30
Table 5. World Health Spending by Region, $ bn, 2013-2020    38
Table 6.  Main Product Trends and Market Opportunities in Global Preventive Vaccines Market    42
Table 7. Global Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    50
Table 8. Global Preventive Vaccines Market by Disease, 2022-2032, $ mn    60
Table 9. Global Preventive Vaccines Market by Administration, 2022-2032, $ mn    71
Table 10. Global Preventive Vaccines Market by Patient, 2022-2032, $ mn    78
Table 11. Global Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn    81
Table 12. Global Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn    83
Table 13. Global Preventive Vaccines Market by Region, 2022-2032, $ mn    85
Table 14.  Leading National Preventive Vaccines Market, 2022 and 2032, $ mn    87
Table 15. North America Preventive Vaccines Market by Country, 2022-2032, $ mn    90
Table 16. U.S. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    94
Table 17. U.S. Preventive Vaccines Market by Disease, 2022-2032, $ mn    94
Table 18. U.S. Preventive Vaccines Market by Administration, 2022-2032, $ mn    95
Table 19. Canada Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    97
Table 20. Canada Preventive Vaccines Market by Disease, 2022-2032, $ mn    97
Table 21. Canada Preventive Vaccines Market by Administration, 2022-2032, $ mn    98
Table 22. Mexico Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    100
Table 23. Mexico Preventive Vaccines Market by Disease, 2022-2032, $ mn    100
Table 24. Mexico Preventive Vaccines Market by Administration, 2022-2032, $ mn    101
Table 25. Europe Preventive Vaccines Market by Country, 2022-2032, $ mn    105
Table 26. Germany Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    107
Table 27. Germany Preventive Vaccines Market by Disease, 2022-2032, $ mn    107
Table 28. Germany Preventive Vaccines Market by Administration, 2022-2032, $ mn    108
Table 29. U.K. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    110
Table 30. U.K. Preventive Vaccines Market by Disease, 2022-2032, $ mn    110
Table 31. U.K. Preventive Vaccines Market by Administration, 2022-2032, $ mn    111
Table 32. France Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    113
Table 33. France Preventive Vaccines Market by Disease, 2022-2032, $ mn    113
Table 34. France Preventive Vaccines Market by Administration, 2022-2032, $ mn    114
Table 35. Spain Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    116
Table 36. Spain Preventive Vaccines Market by Disease, 2022-2032, $ mn    116
Table 37. Spain Preventive Vaccines Market by Administration, 2022-2032, $ mn    117
Table 38. Italy Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    119
Table 39. Italy Preventive Vaccines Market by Disease, 2022-2032, $ mn    119
Table 40. Italy Preventive Vaccines Market by Administration, 2022-2032, $ mn    120
Table 41. Russia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    122
Table 42. Russia Preventive Vaccines Market by Disease, 2022-2032, $ mn    122
Table 43. Russia Preventive Vaccines Market by Administration, 2022-2032, $ mn    123
Table 44. Preventive Vaccines Market in Rest of Europe by Country, 2022-2032, $ mn    125
Table 45. APAC Preventive Vaccines Market by Country, 2022-2032, $ mn    128
Table 46. Japan Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    132
Table 47. Japan Preventive Vaccines Market by Disease, 2022-2032, $ mn    132
Table 48. Japan Preventive Vaccines Market by Administration, 2022-2032, $ mn    133
Table 49. China Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    135
Table 50. China Preventive Vaccines Market by Disease, 2022-2032, $ mn    135
Table 51. China Preventive Vaccines Market by Administration, 2022-2032, $ mn    136
Table 52. Australia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    138
Table 53. Australia Preventive Vaccines Market by Disease, 2022-2032, $ mn    138
Table 54. Australia Preventive Vaccines Market by Administration, 2022-2032, $ mn    139
Table 55. India Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    141
Table 56. India Preventive Vaccines Market by Disease, 2022-2032, $ mn    141
Table 57. India Preventive Vaccines Market by Administration, 2022-2032, $ mn    142
Table 58. South Korea Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    144
Table 59. South Korea Preventive Vaccines Market by Disease, 2022-2032, $ mn    144
Table 60. South Korea Preventive Vaccines Market by Administration, 2022-2032, $ mn    145
Table 61. Preventive Vaccines Market in Rest of APAC by Country/Region, 2022-2032, $ mn    147
Table 62. South America Preventive Vaccines Market by Country, 2022-2032, $ mn    150
Table 63. Argentina Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    152
Table 64. Argentina Preventive Vaccines Market by Disease, 2022-2032, $ mn    152
Table 65. Argentina Preventive Vaccines Market by Administration, 2022-2032, $ mn    153
Table 66. Brazil Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    155
Table 67. Brazil Preventive Vaccines Market by Disease, 2022-2032, $ mn    155
Table 68. Brazil Preventive Vaccines Market by Administration, 2022-2032, $ mn    156
Table 69. Chile Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    158
Table 70. Chile Preventive Vaccines Market by Disease, 2022-2032, $ mn    158
Table 71. Chile Preventive Vaccines Market by Administration, 2022-2032, $ mn    159
Table 72. MEA Preventive Vaccines Market by Country, 2022-2032, $ mn    163
Table 73. UAE Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    165
Table 74. UAE Preventive Vaccines Market by Disease, 2022-2032, $ mn    165
Table 75. UAE Preventive Vaccines Market by Administration, 2022-2032, $ mn    166
Table 76. Saudi Arabia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    168
Table 77. Saudi Arabia Preventive Vaccines Market by Disease, 2022-2032, $ mn    168
Table 78. Saudi Arabia Preventive Vaccines Market by Administration, 2022-2032, $ mn    169
Table 79. South Africa Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn    171
Table 80. South Africa Preventive Vaccines Market by Disease, 2022-2032, $ mn    171
Table 81. South Africa Preventive Vaccines Market by Administration, 2022-2032, $ mn    172
Table 82. AstraZeneca plc: Company Snapshot    178
Table 83. AstraZeneca plc: Business Segmentation    179
Table 84. AstraZeneca plc: Product Portfolio    179
Table 85. Bavarian Nordic A/S: Company Snapshot    180
Table 86. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020    181
Table 87. China National Biotec Group Company Ltd.: Company Snapshot    183
Table 88. CSL Ltd.: Company Snapshot    185
Table 89. Daiichi Sankyo Co. Ltd.: Company Snapshot    187
Table 90. Emergent BioSolutions Inc.: Company Snapshot    189
Table 91. GlaxoSmithKline: Company Snapshot    191
Table 92. GlaxoSmithKline: Business Segmentation    192
Table 93. GlaxoSmithKline: Product Portfolio    193
Table 94. GlaxoSmithKline: Revenue, 2018-2020, $ bn    194
Table 95. GlaxoSmithKline: Recent Developments    194
Table 96. Johnson & Johnson: Company Snapshot    195
Table 97. Johnson & Johnson: Business Segments    196
Table 98. Merck & Co., Inc.: Company Snapshot    197
Table 99. Merck & Co., Inc.: Business Segmentation    197
Table 100. Merck & Co., Inc.: Revenue, 2018-2020, $ bn    198
Table 101. Moderna Inc.: Company Snapshot    199
Table 102. Novavax, Inc.: Company Snapshot    200
Table 103. Pfizer Inc.: Company Snapshot    202
Table 104. Pfizer Inc.: Business Segmentation    203
Table 105. Pfizer Inc.: Product Portfolio    204
Table 106. Pfizer Inc.: Revenue, 2018-2020, $ bn    205
Table 107. Pfizer Inc.: Recent Developments    205
Table 108. Sanofi: Company Snapshot    206
Table 109. Sanofi: Business Segmentation    206
Table 110. Sanofi: Revenue, 2018-2020, $ bn    208
Table 111. Takeda Pharmaceutical Co. Ltd.: Company Snapshot    209


List of Figures

Figure 1. Research Method Flow Chart    14

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation    17

Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032    19

Figure 4. Global Preventive Vaccines Market, 2022-2032, $ mn    22

Figure 5. Development Stages of Preventive Vaccines    23

Figure 6. Impact of COVID-19 on Business    27

Figure 7. Primary Drivers and Impact Factors of Global Preventive Vaccines Market    33

Figure 8.  Leading Causes of Death in the World, 2000 and 2019, million    36

Figure 9.  Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million    37

Figure 10. World Population 65 and Over, % of Total Population, 1950-2060    37

Figure 11. Primary Restraints and Impact Factors of Global Preventive Vaccines Market    39

Figure 12. Investment Opportunity Analysis    43

Figure 13. Porter’s Fiver Forces Analysis of Global Preventive Vaccines Market    46

Figure 14. Breakdown of Global Preventive Vaccines Market by Vaccine Type, 2022-2032, % of Revenue    51

Figure 15. Global Addressable Market Cap in 2023-2032 by Vaccine Type, Value ($ mn) and Share (%)    51

Figure 16. Global Preventive Vaccines Market by Vaccine Type: Live/Attenuated Vaccines, 2022-2032, $ mn    52

Figure 17. Global Preventive Vaccines Market by Vaccine Type: Inactivated Vaccines, 2022-2032, $ mn    53

Figure 18. Global Preventive Vaccines Market by Vaccine Type: Subunit Vaccines, 2022-2032, $ mn    54

Figure 19. Global Preventive Vaccines Market by Vaccine Type: Toxoid Vaccines, 2022-2032, $ mn    55

Figure 20. Global Preventive Vaccines Market by Vaccine Type: Conjugate Vaccines, 2022-2032, $ mn    56

Figure 21. Global Preventive Vaccines Market by Vaccine Type: mRNA Vaccines, 2022-2032, $ mn    57

Figure 22. Global Preventive Vaccines Market by Vaccine Type: Recombinant Vector Vaccines, 2022-2032, $ mn    58

Figure 23. Global Preventive Vaccines Market by Vaccine Type: Other Vaccines, 2022-2032, $ mn    59

Figure 24. Breakdown of Global Preventive Vaccines Market by Disease, 2022-2032, % of Sales Revenue    61

Figure 25. Global Addressable Market Cap in 2023-2032 by Disease, Value ($ mn) and Share (%)    61

Figure 26. Global Preventive Vaccines Market by Disease: Pneumococcal Disease, 2022-2032, $ mn    62

Figure 27. Global Preventive Vaccines Market by Disease: Poliovirus, 2022-2032, $ mn    63

Figure 28. Global Preventive Vaccines Market by Disease: Hepatitis, 2022-2032, $ mn    64

Figure 29. Global Preventive Vaccines Market by Disease: Influenza, 2022-2032, $ mn    65

Figure 30. Global Preventive Vaccines Market by Disease: Measles, Mumps, and Rubella (MMR), 2022-2032, $ mn    66

Figure 31. Global Preventive Vaccines Market by Disease: Varicella, 2022-2032, $ mn    67

Figure 32. Global Preventive Vaccines Market by Disease: Human Papilloma Virus, 2022-2032, $ mn    68

Figure 33. Global Preventive Vaccines Market by Disease: COVID-19, 2022-2032, $ mn    69

Figure 34. Global Preventive Vaccines Market by Disease: Other Diseases, 2022-2032, $ mn    70

Figure 35. Breakdown of Global Preventive Vaccines Market by Administration, 2022-2032, % of Sales Revenue    72

Figure 36. Global Addressable Market Cap in 2023-2032 by Administration, Value ($ mn) and Share (%)    72

Figure 37. Global Preventive Vaccines Market by Administration: Intramuscular Route, 2022-2032, $ mn    73

Figure 38. Global Preventive Vaccines Market by Administration: Subcutaneous Route, 2022-2032, $ mn    74

Figure 39. Global Preventive Vaccines Market by Administration: Oral Route, 2022-2032, $ mn    75

Figure 40. Global Preventive Vaccines Market by Administration: Intravenous Injection, 2022-2032, $ mn    76

Figure 41. Global Preventive Vaccines Market by Administration: Other Administration Routes, 2022-2032, $ mn    77

Figure 42. Breakdown of Global Preventive Vaccines Market by Patient, 2022-2032, % of Revenue    79

Figure 43. Global Addressable Market Cap in 2023-2032 by Patient, Value ($ mn) and Share (%)    79

Figure 44. Global Preventive Vaccines Market by Patient: Pediatric Vaccines, 2022-2032, $ mn    80

Figure 45. Global Preventive Vaccines Market by Patient: Adult Vaccines, 2022-2032, $ mn    82

Figure 46.  Global Market Snapshot by Region    84

Figure 47.  Geographic Spread of Worldwide Preventive Vaccines Market, 2022-2032, % of Sales Revenue    85

Figure 48. Global Addressable Market Cap in 2023-2032 by Region, Value ($ mn) and Share (%)    86

Figure 49.  North American Preventive Vaccines Market, 2022-2032, $ mn    89

Figure 50. Breakdown of North America Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue    90

Figure 51. Contribution to North America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)    91

Figure 52. U.S. Preventive Vaccines Market, 2022-2032, $ mn    93

Figure 53. Canada Preventive Vaccines Market, 2022-2032, $ mn    96

Figure 54.  Preventive Vaccines Market in Mexico, 2022-2032, $ mn    99

Figure 55.  European Preventive Vaccines Market, 2022-2032, $ mn    103

Figure 56. Breakdown of European Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue    104

Figure 57. Contribution to Europe 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)    105

Figure 58.  Preventive Vaccines Market in Germany, 2022-2032, $ mn    106

Figure 59.  Preventive Vaccines Market in U.K., 2022-2032, $ mn    109

Figure 60.  Preventive Vaccines Market in France, 2022-2032, $ mn    112

Figure 61.  Preventive Vaccines Market in Spain, 2022-2032, $ mn    115

Figure 62.  Preventive Vaccines Market in Italy, 2022-2032, $ mn    118

Figure 63.  Preventive Vaccines Market in Russia, 2022-2032, $ mn    121

Figure 64.  Preventive Vaccines Market in Rest of Europe, 2022-2032, $ mn    124

Figure 65. Asia-Pacific Preventive Vaccines Market, 2022-2032, $ mn    127

Figure 66. Breakdown of APAC Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue    127

Figure 67. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)    129

Figure 68.  Preventive Vaccines Market in Japan, 2022-2032, $ mn    131

Figure 69.  Preventive Vaccines Market in China, 2022-2032, $ mn    134

Figure 70.  Preventive Vaccines Market in Australia, 2022-2032, $ mn    137

Figure 71.  Preventive Vaccines Market in India, 2022-2032, $ mn    140

Figure 72.  Preventive Vaccines Market in South Korea, 2022-2032, $ mn    143

Figure 73.  Preventive Vaccines Market in Rest of APAC, 2022-2032, $ mn    146

Figure 74. South America Preventive Vaccines Market, 2022-2032, $ mn    149

Figure 75. Breakdown of South America Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue    149

Figure 76. Contribution to South America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)    150

Figure 77.  Preventive Vaccines Market in Argentina, 2022-2032, $ mn    151

Figure 78.  Preventive Vaccines Market in Brazil, 2022-2032, $ mn    154

Figure 79.  Preventive Vaccines Market in Chile, 2022-2032, $ mn    157

Figure 80.  Preventive Vaccines Market in Rest of South America, 2022-2032, $ mn    160

Figure 81. Preventive Vaccines Market in Middle East and Africa (MEA), 2022-2032, $ mn    162

Figure 82. Breakdown of MEA Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue    162

Figure 83. Contribution to MEA 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)    163

Figure 84.  Preventive Vaccines Market in UAE, 2022-2032, $ mn    164

Figure 85.  Preventive Vaccines Market in Saudi Arabia, 2022-2032, $ mn    167

Figure 86.  Preventive Vaccines Market in South Africa, 2022-2032, $ mn    170

Figure 87. Growth Stage of Global Preventive Vaccines Industry over the Forecast Period    174

Research methodology is mainly referring to the practical how of any offered piece of research. More specifically, it’s all about how a researcher systematically designs a study in order to assure extremely valid as well as reliable results that ultimately address the targets and objectives of the research.

In any formal research including academic journal, article, dissertation and so on, there will be a special section on a research methodology that mainly describes what, by whom, how to gather as well as how to evaluate the data are provided.

This research methodology has been segmented into following types:

Primary Research:

It is said to be original information that the researchers collect for the crucial purposes of answering the research questions of readers with the help of surveys, observations and experiments.

Secondary Research:

The secondary research is the data that has already been collected by various other researchers in the form of government analysis or scientific studies.

Qualitative Research:

It is descriptive and subjective method irrespective of facts. Both observation and description are essential in this type of research methodology. Its main vision is to analyze knowledge, attitudes, behaviours as well as opinions of people related to the topic of any research. This method has been operated through grounded research, case study and actionable research.

Quantitative Research:

It contains several laboratory experiments, basic surveys, mathematical calculations, simulations and so on. The possible measurement, quantity or amount is considered to be a major factor in the quantitative research methodology.

Tab Four
Our Happy

Clients